Key result
Sirolimus-eluting stents significantly reduced the frequency of major adverse cardiac events compared to bare metal stents (8.6% vs 35.7%, P<0.001) at 15 months in complex coronary artery lesions.
Why the study?
Do sirolimus-eluting stents reduce target vessel revascularisation and major adverse cardiac events in patients with symptomatic complex coronary artery disease compared to bare metal stents?
Population
322 patients with symptomatic complex coronary artery disease
Comparison
Sirolimus-eluting stents (SES) vs Bare metal stents (BMS)
Design
RCT, randomly assigned
Follow-up
15 months
Authors
Loading...
Supports sirolimus-eluting stents in complex lesions; confirms benefit persists after dual antiplatelet therapy cessation.
RCT (n=322)
randomly assigned
Do sirolimus-eluting stents reduce target vessel revascularisation and major adverse cardiac events in patients with symptomatic complex coronary artery disease compared to bare metal stents?
Absolute Event Rate: 8.6% vs 35.7%
p-value: p=<0.001
Sirolimus-eluting stents significantly reduce target vessel revascularization and MACE at 15 months compared to bare metal stents in complex coronary lesions, even after cessation of dual antiplatelet therapy.
Helqvist et al. (2007) conducted an RCT in symptomatic complex coronary artery disease (n=322). Sirolimus-eluting stents (SES) vs. Bare metal stents (BMS) was evaluated on Major adverse cardiac events (p=<0.001). Sirolimus-eluting stents significantly reduced the frequency of major adverse cardiac events compared to bare metal stents (8.6% vs 35.7%, P<0.001) at 15 months in complex coronary artery lesions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: